2. Кобалава Ж.Д., Конради А.О., Недогода С.В. и др. Артериальная гипертензия у взрослых. Клинические рекомендации 2020. Российский кардиологический журнал. 2020;25(3):3786.

3. Algharally E.A.-H., Kreutz R. Classes of antihypertensive drugs. European Society of Hypertension Guidelines on Hypertension: CRC Press; 2019. Р. 325–35.

4. Kreutz R., Algarabelli E.A.-H. Antihypertensive drugs. In: Offermanns S, Rosenthal W, editors. Encyclopedia of molecular pharmacology. Cham: Springer International Publishing House; 2021. Р. 165–74.

5. Rea F., et al. Initial Antihypertensive Treatment Strategies and Therapeutic Inertia: Evidence From a Large Population-Based Cohort. Hypertension. 2018;72(4):846–53.

6. Savare L., et al. Use of initial and subsequent antihypertensive combination treatment in the last decade: analysis of a large Italian database. J Hypertens. 2022;40(9):1768–75.

7. Романенко В.В., Романенко З.В. Ингибиторы АПФ – препараты первой линии в лечении сердечно-сосудистых заболеваний. Международные обзоры: клиническая практика и здоровье. 2014;3(9).

8. Savarese G., et al. A meta-analysis reporting effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients without heart failure. J Am College Cardiol. 2013;61(2):131–42.

9. Burnett H., et al. Thirty years of evidence on the efficacy of drug treatments for chronic heart failure with reduced ejection fraction: a network meta-analysis. Circulation: Heart Failure. 2017;10(1):e003529.

10. Van Vark L.C., et al. Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin–angiotensin–aldosterone system inhibitors involving 158 998 patients. Eur Heart J. 2012;33(16):2088–97.

11. Messerli F.H., et al. Angiotensin-converting enzyme inhibitors in hypertension: to use or not to use? J Am College Cardiol. 2018;71(13):1474–82.

12. Gallo G., Volpe M., Rubattu S. Angiotensin receptor blockers in the management of hypertension: a real-world perspective and current recommendations. Vasc Health Risk Management. 2022. Р. 507–15.

13. Reboldi G., et al. Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysis. J Hypertens. 2008;26(7):1282–89.

14. Corrao G., et al. Discontinuation of and changes in drug therapy for hypertension among newly-treated patients: a population-based study in Italy. J Hypertens. 2008;26(4):819–24.

15. Bhandari S., et al. Renin-angiotensin system inhibition in advanced chronic kidney disease. N Engl J Med. 2022;387(22):2021–32.

16. Sarafidis P.A., et al. Prevalence and factors associated with hyperkalemia in predialysis patients followed in a low-clearance clinic. Clin J Am Soc Nephrol: CJASN. 2012;7(8):1234.

17. Moen M.F., et al. Frequency of hypoglycemia and its significance in chronic kidney disease. Clin J Am Soc Nephrol: CJASN. 2009;4(6):1121.

18. Epstein M., et al. Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors. Am J Manag Care. 2015;21(Suppl. 11):S212–20.

19. Yildirim T., et al. Major barriers against renin–angiotensin–aldosterone system blocker use in chronic kidney disease stages 3–5 in clinical practice: a safety concern? Renal Failure. 2012;34(9):1095–99.

20. Fu E.L., et al. Stopping renin-angiotensin system inhibitors in patients with advanced CKD and risk of adverse outcomes: a nationwide study. J Am Soc Nephrol: JASN. 2021;32(2):424.

21. Yang A., et al. Clinical outcomes following discontinuation of renin-angiotensin-system inhibitors in patients with type 2 diabetes and advanced chronic kidney disease: A prospective cohort study. EClinicalMedicine. 2023;55.

22. Sarafidis P.A., Khosla N., Bakris G.L. Antihypertensive therapy in the presence of proteinuria. Am J Kidney Dis. 2007;49(1):12–26.

23. Ott C., Schmieder R.E. Diagnosis and treatment of arterial hypertension 2021. Kidney Int. 2022;101(1):36–46.

24. Chandy D., Aronov W.S., Banach M. Current perspectives on treatment of hypertensive patients with chronic obstructive pulmonary disease. Integrat. Blood Pressure Control. 2013;6:101–9.

25. Mancini G.B.J., Etminan M., Zhang B., et al. Reduction of morbidity and mortality statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. JACC. 2006;47 (12):2554–60.

26. Thomopoulos C., Parati G., Zanchetti A. Effects of blood pressure-lowering on outcome incidence in hypertension: 5. Head-to-head comparisons of various classes of antihypertensive drugs–overview and meta-analyses. J Hypertens. 2015;33(7):1321–41.

27. Wang Y.C., et al. Risks of adverse events following coprescription of statins and calcium channel blockers: a nationwide population-based study. Medicine. 2016;95(2).

28. Xu Y., et al. Concomitant use of diltiazem with direct oral anticoagulants and bleeding risk in atrial fibrillation. J Am Heart Associat. 2022;11(14):e025723.

29. Pham P., et al. Association of oral anticoagulants and verapamil or diltiazem with adverse bleeding events in patients with nonvalvular atrial fibrillation and normal kidney function. JAMA network open. 2020;3(4):e203593.

30. Wei J., et al. Comparison of cardiovascular events among users of different classes of antihypertension medications: a systematic review and network meta-analysis. JAMA Network Open. 2020;3(2):e1921618–618.

31. Psaty B.M., et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA. 2003;289(19):2534–44.

32. Chalmers J., et al. Benefit of treatment based on indapamide mostly combined with perindopril on mortality and cardiovascular outcomes: a pooled analysis of four trials. J Hypertens. 2023;41(3):508.

33. Roush G.C., et al. Head-to-head comparisons of hydrochlorothiazide with indapamide and chlorthalidone: antihypertensive and metabolic effects. Hypertension. 2015;65(5):1041–46.

34. Olde Engberink R.H.G., et al. Effects of thiazide-type and thiazide-like diuretics on cardiovascular events and mortality: systematic review and meta-analysis. Hypertension. 2015;65(5):1033–40.

35. Brown M.J., et al. Effect of amiloride, or amiloride plus hydrochlorothiazide, versus hydrochlorothiazide on glucose tolerance and blood pressure (PATHWAY-3): a parallel-group, double-blind randomised phase 4 trial. Lancet Diab Endocrinol. 2016;4(2):136–47.

36. Zillich A.J., et al. Thiazide diuretics, potassium, and the development of diabetes: a quantitative review. Hypertension. 2006;48(2):219–24.

37. Карпов Ю.А., Мелехов А.В. Валсартан – ключ к решению вопросов профилактики сердечно-сосудистых заболеваний. Атмосфера. Новости кардиологии. 2018;1.

38. Леонова М.В. Валсартан: от клинической фармакологии к гипотензивной эффективности и фармакоэкономическим преимуществам в лечении артериальной гипертонии. Справочник поликлинического врача. 2013;9:11–6.

39. Nixon R.M., Muller E., Lowy A., Falvey H. Valsartan vs. other angiotensin II receptor blockers in the treatment of hypertension: a meta-analytical approach. Int J Clin Pract. 2009;63(5):766–75.

40. Ogihara T., Saruta T., Rakugi H., et al. Valsartan in Elderly Isolated Systolic Hypertension Study Group. Target blood pressure for treatment of isolated systolic hypertension in the elderly: valsartan in elderly isolated systolic hypertension study. Hypertension. 2010;56(2):196–202.

41. Преображенский Д.В., Носенко Н.С., Некрасова Н.И. и др. Антагонист кальция третьего поколения амлодипин: особенности клинической фармакологии и спектр терапевтического применения. Русский медицинский журнал. 2011;14:884. Preobrazhensky D.V., Nosenko N.S., Nekrasova N.I. et al. Third generation calcium antagonist amlodipine: features of clinical pharmacology and range of therapeutic use. Russkii meditsinskii zhurnal. 2011;14:884. (In Russ.)].

42. Леонова М.В. Клиническая фармакология и клиническая эффективность амлодипина. Данные доказательной медицины. Медицинский совет. 2014;(12):25–32. Leonova M.V. Clinical pharmacology and clinical efficacy of amlodipine. Data from evidence-based medicine. Meditsinskii sovet. 2014;(12):25–32. (In Russ.)]. Doi: 10.21518/2079-701X-2014-12-25-32.

43. Levine C.B., Fahrbach K.R., Frame D., et al. Effect of amlodipine on systolic blood pressure. Clin Ther. 2003;25:35–57.

44. Духанин А.С., Подзолков В.И., Тарзиманова А.И. Амлодипин в лечении артериальной гипертензии: всегда ли генерик эквивалентен оригинальному препарату? Русский медицинский журнал. Кардиология. 2010;18(9):556–59. Dukhanin A.S., Podzolkov V.I., Tarzimanova A.I. Amlodipine in the treatment of arterial hypertension: is the generic always equivalent to the original drug? Russkii meditsinskii zhurnal. Kardiologiya. 2010;18(9):556–59. (In Russ.)].

45. Xie M., Tang T., Liang H. Efficacy of single-pill combination in uncontrolled essential hypertension: A systematic review and network meta-analysis. Clin Cardiol. 2023;46(8):886–98. Doi: 10.1002/clc.24082.

46. Wilke Th., Weisser B., Predel H.-G., et al. Effects of Single Pill Combinations Compared to Identical Multi Pill Therapy on Outcomes in Hypertension, Dyslipidemia and Secondary Cardiovascular Prevention: Integr. Blood Press. Control. 2022;15:11–21. Doi: 10.2147/IBPC.S336324.

47. Julius S., Kjeldsen S.E., Weber M., et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipin: the VALUE randomized trial. Lancet. 2004;363(9426):2022–31.

48. Чазова И.Е., Карпов Ю.А., Вигдорчик А.В. Эффективность и безопасность комбинации амлодипина и валсартана в лечении артериальной гипертонии в условиях реальной клинической практики: первые результаты российского наблюдательного исследования ЭКСТРА. Системные гипертензии. 2010;2:18–26.

49. Карпов Ю.А., Чазова И.Е., Вигдорчик А.В., Зазулина А.Ю. Эффективность и безопасность фиксированной комбинации амлодипина и валсартана в лечении артериальной гипертонии в условиях реальной клинической практики: результаты Российского наблюдательного исследования ЭКСТРА-2. Кардиологический вестник. 2010;5:39–46.

50. Чазова И.Е., Фомин В.В., Разуваева М.А., Вигдорчик А.В. Фиксированная комбинация валсартана и амлодипина в лечении резистентной и неконтролируемой артериальной гипертонии (Российский регистр неконтролируемой и резистентной артериальной гипертензии РЕГАТА-ЭКСТРА «Резистентная Гипертония АрТериальная – ЭКСфорж в Терапии Резистентной Артериальной гипертензии»). Системные гипертензии. 2011;8(1):5–9.

51. Бубнова М.А., Крючкова О.Н., Ицкова Е.А. и др. Эффективность применения комбинаций периндоприл/амлодипин и валсартан/амлодипин у пациентов с сочетанием артериальной гипертензии и хронической обструктивной болезни легких. Южно-Российский журнал терапевтической практики. 2022;3(1):42–9.

52. Su F., Xia Q. Effects of Valsartan and Amlodipine Tablets Combined with β-Lipoic Acid on T-AOC, IL-6 and β2-MG Levels in Patients with Diabetic Nephropathy. Altern Ther Health Med. 2023;29(5):126–31.

53. Zhang W., Song Y., Xu J. Effectiveness and safety of valsartan/amlodipine in hypertensive patients with stroke: China Status II subanalysis. Medicine (Baltimore). 2017;96(26):e7172. Doi: 10.1097/MD.0000000000007172.

54. Malesker M.A., Hilleman D.E. Comparison of amlodipine/valsartan fixed-dose combination therapy and conventional therapy. Manag Care. 2010;19(7):36–42.